Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
SPN-812 Phase 3 Results Expected
SPN-812 • Attention-Deficit/Hyperactivity Disorder
Target Indication
Attention-Deficit/Hyperactivity Disorder
Clinical Trial
NCT02736656Last updated: 12/4/2025